Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lunesta Clears FDA; Sepracor Plans 2005 Release Of Depression Data

Executive Summary

Sepracor plans to present data from its completed Lunesta (eszopiclone) Phase IIIb/IV trial for the treatment of insomnia in patients suffering from depression in 2005

You may also be interested in...



Ambien CR Approval Includes Sleep Maintenance, Long-Term Use

The approval of Sanofi-Aventis' Ambien CR (zolpidem extended-release) includes claims for sleep maintenance and long-term use that will allow the insomnia medication to compete against newer agents

Ambien CR Approval Includes Sleep Maintenance, Long-Term Use

The approval of Sanofi-Aventis' Ambien CR (zolpidem extended-release) includes claims for sleep maintenance and long-term use that will allow the insomnia medication to compete against newer agents

Takeda To Highlight Rozerem Melatonin Receptor Mechanism Of Action

Takeda's Rozerem promotions will highlight ramelteon's melatonin receptor activity and lack of abuse potential following FDA approval of the insomnia therapy

Related Content

UsernamePublicRestriction

Register

PS045134

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel